Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AgfiledCriticalBayer Ag
Priority to CU20000065ApriorityCriticalpatent/CU23150A3/en
Publication of CU23150A3publicationCriticalpatent/CU23150A3/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La invencion se refiere a formulaciones de medicamento que comprenden como sustancia activa Acido 1-ciclopropil-7-( [S,S]-2,8-diazabiciclo [4.3.0] non-8-il)-6-fluor-1,4-dihidro-8-metoxi-4oxo-3-quinolocarboxílico y/o sales farmacÉuticamente aceptables de este y/o hidratos de este, que liberen la sustancia activa que contienen con una liberacion definida.The invention relates to medicament formulations comprising as active substance Acid 1-cyclopropyl-7- ([S, S] -2,8-diazabicyclo [4.3.0] non-8-yl) -6-fluor-1, 4-dihydro-8-methoxy-4oxo-3-quinolocarboxylic and / or pharmaceutically acceptable salts thereof and / or hydrates thereof, which release the active substance they contain with a defined release.
CU20000065A2000-03-242000-03-24
MEDICINAL FORMULATION WITH CONTROLLED RELEASE OF ACTIVE SUBSTANCE
CU23150A3
(en)
Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them